RxDoctor Payments Data

Gentry Haughton, DPM

Foot & Ankle Surgery · Shreveport, LANPI 1316171358

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,258 of the $9,719 with a category attached, or 85.0%. 11 manufacturers reported payments, led by Convatec Inc. at 30.0% of the total. Reporting peaked in 2024 at $3,119 and has fallen 62.5% since, to $1,171 in 2025.

$9,719in general payments, 2019–2025

Across 231 payments — averaging $42.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$3K
  • Organogenesis Inc.$2K
  • AbbVie$2K
  • Melinta Therapeutics, LLC$1K
  • Kerecis Limited$723
  • Paratek Pharmaceuticals, Inc.$492
  • plus $223 from 5 others

What the payments were for

  • Travel & lodging$1,46215%
  • Food & beverage$8,25885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,719 in reported general payments places this provider in the 80th percentile of 92 foot & ankle surgery providers in Louisiana.

See all foot & ankle surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$81,530
Medicare patients
407
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pregabalin262$8,088
Gabapentin619$5,323
Clobetasol Propionate60$4,870
Terbinafine Hcl414$3,805
Duloxetine Hcl206$3,222
Diclofenac Sodium26$1,053
Doxycycline Hyclate69$656
Meloxicam108$394
Clotrimazole18$295
Fluconazole11$213
Silver Sulfadiazine13$115
Clindamycin Hcl13$96
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$52

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →